BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis - 2Hilary Duff releases 'Mature,' her 1st song in 10 years
- 3Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- 4Vote in favor of your #1 Kind of Cap
- 5UN experts urge investigation into Israel’s killing of Lebanese journalists
- Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman?
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Vote In favor of Your #1 Compelling Female Producer
- 10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\
- 5 Instructive Toy Brands for Youngsters
- Figure out How to Plan for Your Web-based Degree monetarily
- The Best Design Bloggers for Style Motivation
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
